StockWatch: Pfizer Scales Patent Cliff by Pursuing Seagen Deal

Pfizer's interest in acquiring Seagen stems from a need to recoup patent cliff revenue losses by replenishing its pipeline, analysts say.

Related Keywords

Gregory Renza ,Reni Benjamin ,Andrew Berens ,Berenberg Zhiqiang Shu ,Bill Dunn ,Asthika Goonewardene ,Matthew Harrison ,Dane Leone ,Astellas Pharma ,Michael Schmidt ,Teresa Buracchio ,Josh Schimmer ,Merck Seagen ,Raymond James ,Jay Olson ,Etzer Darout ,Reata Pharmaceuticals ,Head Of Biotech Industry Research ,Vaccine Alliance ,Pfizer ,Merck Kga ,Morgan Stanley ,Merck Co ,Merck Kgaa ,Ladenburg Thalmann ,Biotech Team ,Office Of Neuroscience ,Wall Street Journal ,Berenberg Capital ,Zhiqiang Shu ,Senior Managing Director ,Targeted Oncology ,Senior Analyst ,Truist Securities ,Biotech Industry Research ,